American Century Companies
LENZ

American Century Companies’s LENZ Therapeutics LENZ Stock Holding History

American Century Companies’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,109
Closed -$882K – 2893
2025
Q2 		$882K Sell
30,109
-296
-1% -$8.05K ﹤0.01% 2338
2025
Q1 		$782K Sell
30,405
-2,101
-6% -$51.7K ﹤0.01% 2339
2024
Q4 		$938K Buy
32,506
+8,631
+36% +$263K ﹤0.01% 2277
2024
Q3 		$567K Buy
+23,875
New +$530K ﹤0.01% 2435

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

American Century Companies's LENZ Position: Q3 2025 in Review

American Century Companies sold out of LENZ Therapeutics (LENZ) in Q3 2025, closing a stake of 30,109 shares — an estimated $882K sold.

American Century Companies first reported a position in LENZ in Q3 2024 and held it in 4 quarters. The position peaked at $938K in Q4 2024. 166 funds tracked by Wall St. Rank hold LENZ as of Q3 2025.

  • American Century Companies reported no remaining LENZ Therapeutics position as of Q3 2025 after selling out during the quarter.
  • American Century Companies sold 30,109 LENZ Therapeutics shares in Q3 2025, an estimated $882K.
  • American Century Companies first reported a position in LENZ Therapeutics in Q3 2024 and held it in 4 quarters.
  • American Century Companies's LENZ Therapeutics position peaked at $938K in Q4 2024.
  • 166 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2025.

Based on American Century Companies's 13F filing for Q3 2025, filed 12 Nov 2025.